cloprostenol

Summary

Summary: A synthetic prostaglandin F2alpha analog. The compound has luteolytic effects and is used for the synchronization of estrus in cattle.

Top Publications

  1. doi In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line
    Emmanuelle Brasnu
    Department of Ophthalmology III, Quinze Vingts National Ophthalmology Hospital, Paris, France
    Curr Eye Res 33:303-12. 2008
  2. doi Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues
    Anuradha Jayaprakasam
    Ophthalmology Department, Broomfield Hospital, Court Road, Chelmsford, Essex
    Orbit 29:357-9. 2010
  3. doi Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination
    Marco Centofanti
    Unità Dipartimentale Semplice di Glaucoma, University of Tor Vergata, Rome, Italy Istituto di Ricovero e Cura a Carattere Scientifico Fondazione G B Bietti, Rome, Italy
    Am J Ophthalmol 150:575-80. 2010
  4. ncbi Effects of oxidative stress in trabecular meshwork cells are reduced by prostaglandin analogues
    Alice L Yu
    Department of Ophthalmology, Ludwig Maximilians University, Munich, Germany
    Invest Ophthalmol Vis Sci 49:4872-80. 2008
  5. pmc Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes
    Y Liang
    Departments of Biological and Chemical Sciences, Allergan Inc, Irvine, CA, USA
    Br J Pharmacol 154:1079-93. 2008
  6. ncbi Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension
    L Jay Katz
    Wills Eye Hospital, Philadelphia, PA 19107, USA
    Am J Ophthalmol 149:661-671.e1. 2010
  7. ncbi Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension
    Monique P Curran
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs Aging 26:1049-71. 2009
  8. doi Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, and anagen prolongation by bimatoprost
    M Tauchi
    Institute of Anatomy II, University of Erlangen Nuremberg, Erlangen, Germany
    Br J Dermatol 162:1186-97. 2010
  9. doi Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth
    Joel L Cohen
    AboutSkin Dermatology and DermSurgery, Englewood and Lone Tree, Colorado, USA
    Dermatol Surg 36:1361-71. 2010
  10. doi Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid
    R R Ajit
    Manchester Royal Eye Hospital, Manchester, UK
    Eye (Lond) 24:1338-43. 2010

Research Grants

  1. PREVALENCE AND IMPACT OF GLAUCOMA AMONG THE VERY ELDERLY
    David Friedman; Fiscal Year: 2003
  2. PREVALENCE AND IMPACT OF GLAUCOMA AMONG THE VERY ELDERLY
    David Friedman; Fiscal Year: 2002
  3. PREVALENCE AND IMPACT OF GLAUCOMA AMONG THE VERY ELDERLY
    David Friedman; Fiscal Year: 2001
  4. CADHERIN DYNAMICS AND GLAUCOMA
    W Daniel Stamer; Fiscal Year: 2010
  5. OHTS--KRESGE EYE INSTITUTE
    Bret Hughes; Fiscal Year: 2004
  6. OCULAR HYPERTENSION TREATMENT STUDY (OHTS)
    James Brandt; Fiscal Year: 2004
  7. Molecular Basis of Myocilin Function in the Human Eye
    W Stamer; Fiscal Year: 2005
  8. CIGTS-2 Optic Disc Reading Center
    Richard Parrish; Fiscal Year: 2005
  9. Improving the Quality of Diabetes Eye Care
    Paul Lee; Fiscal Year: 2005
  10. NOVEL GLAUCOMA DIAGNOSTICS FOR STRUCTURE AND FUNCTION
    Joel Schuman; Fiscal Year: 2004

Detail Information

Publications211 found, 100 shown here

  1. doi In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line
    Emmanuelle Brasnu
    Department of Ophthalmology III, Quinze Vingts National Ophthalmology Hospital, Paris, France
    Curr Eye Res 33:303-12. 2008
    ....
  2. doi Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues
    Anuradha Jayaprakasam
    Ophthalmology Department, Broomfield Hospital, Court Road, Chelmsford, Essex
    Orbit 29:357-9. 2010
    ..The periorbital fat atrophy is most apparent with uniocular use and both doctors and patients need to be aware of this side effect before commencing treatment. The effects, however, appear to be reversible with treatment cessation...
  3. doi Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination
    Marco Centofanti
    Unità Dipartimentale Semplice di Glaucoma, University of Tor Vergata, Rome, Italy Istituto di Ricovero e Cura a Carattere Scientifico Fondazione G B Bietti, Rome, Italy
    Am J Ophthalmol 150:575-80. 2010
    ....
  4. ncbi Effects of oxidative stress in trabecular meshwork cells are reduced by prostaglandin analogues
    Alice L Yu
    Department of Ophthalmology, Ludwig Maximilians University, Munich, Germany
    Invest Ophthalmol Vis Sci 49:4872-80. 2008
    ....
  5. pmc Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes
    Y Liang
    Departments of Biological and Chemical Sciences, Allergan Inc, Irvine, CA, USA
    Br J Pharmacol 154:1079-93. 2008
    ..Hence, to elucidate the molecular mechanisms of this effect of bimatoprost, we focused on pharmacologically characterizing prostaglandin FP receptor (FP) and FP receptor variant (altFP) complexes...
  6. ncbi Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension
    L Jay Katz
    Wills Eye Hospital, Philadelphia, PA 19107, USA
    Am J Ophthalmol 149:661-671.e1. 2010
    ..To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of ophthalmic formulations of bimatoprost 0.01% and 0.0125% compared with bimatoprost 0.03%...
  7. ncbi Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension
    Monique P Curran
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs Aging 26:1049-71. 2009
    ..Other adverse events included increases in the pigmentation of the iris, perorbital areas and eyelashes...
  8. doi Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, and anagen prolongation by bimatoprost
    M Tauchi
    Institute of Anatomy II, University of Erlangen Nuremberg, Erlangen, Germany
    Br J Dermatol 162:1186-97. 2010
    ..However, as control of eyelash growth and the underlying mechanisms of eyelash hypo- or hypertrichosis are largely obscure, available therapy is limited...
  9. doi Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth
    Joel L Cohen
    AboutSkin Dermatology and DermSurgery, Englewood and Lone Tree, Colorado, USA
    Dermatol Surg 36:1361-71. 2010
    ..Many women desire prominent eyelashes. In December 2008, bimatoprost ophthalmic solution 0.03% was approved for the treatment of hypotrichosis of the eyelashes in the United States...
  10. doi Patterns and rate of adherence to glaucoma therapy using an electronic dosing aid
    R R Ajit
    Manchester Royal Eye Hospital, Manchester, UK
    Eye (Lond) 24:1338-43. 2010
    ..To identify patterns and rates of adherence with travoprost eye drops using the Travatan dosing aid (TDA) and to present a method for graphically presenting adherence data...
  11. ncbi Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical bimatoprost therapy: 2 case reports and review of the literature
    Sayime Aydin
    Ophthalmology Department, Dumlupinar University School of Medicine, Kutahya, Turkey
    Cutan Ocul Toxicol 29:212-6. 2010
    ..To report 2 cases of resolution of orbital fat pad prolapsus and deepening of the lid sulcus caused by topical bimatoprost therapy, and to review the literature...
  12. ncbi Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells
    David A Ammar
    Rocky Mountain Lions Eye Institute, Department of Ophthalmology, University of Colorado Denver School of Medicine, Aurora, 80045, USA
    Adv Ther 27:837-45. 2010
    ..Substitution of BAK with polyquad or sofZia resulted in significantly higher percentages of live conjunctival and corneal cells. Further studies are needed to understand the- clinical implications of these findings...
  13. ncbi Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost
    Juwan Park
    Department of Ophthalmology and Visual Science, St Mary s Hospital, The Catholic University of Korea, Seoul, Korea
    Jpn J Ophthalmol 55:22-7. 2011
    ..To confirm the possible mechanism by which topical prostaglandin antiglaucoma drugs cause a deep superior sulcus...
  14. doi Physicians' treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma
    Steven R Hahn
    Albert Einstein College of Medicine, Bronx, NY, USA
    Curr Med Res Opin 26:957-63. 2010
    ..Efficacy and tolerability influence physicians' decisions and patient persistence, and differences between medications may impact persistence...
  15. pmc Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy
    Gregory Reardon
    Informagenics, LLC, Worthington, Ohio, USA
    BMC Ophthalmol 10:5. 2010
    ..The purpose of the present study was to evaluate persistence with prostaglandin analogs among glaucoma patients in the first therapy year using a modification of a previously published technique...
  16. ncbi Deepening of lid sulcus from topical bimatoprost therapy
    Lee S Peplinski
    Bennett and Bloom Eye Centers, 4010 Dupont Circle, Suite 380, Louisville, KY 40207, USA
    Optom Vis Sci 81:574-7. 2004
    ..To report a new adverse effect related to treatment with bimatoprost...
  17. pmc Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study
    J A Kammer
    Vanderbilt Eye Institute, 2311 Pierce Ave, Nashville, TN 37232 8808, USA
    Br J Ophthalmol 94:74-9. 2010
    ..To evaluate the efficacy and safety of replacing latanoprost with another prostaglandin analogue (PGA) in patients with glaucoma or ocular hypertension requiring additional intraocular pressure (IOP) lowering while on latanoprost...
  18. ncbi Accounting for restart rates in evaluating persistence with ocular hypotensives
    Gail F Schwartz
    Greater Baltimore Medical Center, Baltimore, Maryland, USA
    Ophthalmology 114:648-52. 2007
    ..This study assessed restart rates for 3 prostaglandin analogs by determining the percentage of patients who discontinued and then restarted therapy...
  19. ncbi Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects
    William C Stewart
    Pharmaceutical Research Network, Charleston, SC 29412 2464, USA
    J Glaucoma 12:475-9. 2003
    ..To evaluate short-term conjunctival and corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy individuals...
  20. doi In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells
    Malik Y Kahook
    Department of Ophthalmology, Rocky Mountain Lions Eye Institute, University of Colorado Denver School of Medicine, Aurora, Colorado 80045, USA
    J Ocul Pharmacol Ther 26:259-63. 2010
    ..To determine the effect of 4 formulations of commercially available prostaglandin analogs (PGAs) on human corneal epithelial cells in vitro...
  21. ncbi Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications
    Robert J Noecker
    Department of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Am J Ophthalmol 141:S15-21. 2006
    ..Cost-effectiveness evaluation of monotherapy with the newer lipid class of intraocular pressure (IOP)-lowering medications in glaucoma and ocular hypertension...
  22. ncbi Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study
    M Centofanti
    Fondazione G B Bietti IRCCS, Roma, Italy
    Eur J Ophthalmol 19:66-71. 2009
    ....
  23. doi Latanoprost therapy after sunken eyes caused by travoprost or bimatoprost
    Shunsuke Nakakura
    Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Hyogo Prefecture, Japan
    Optom Vis Sci 88:1140-4. 2011
    ..To report clinical results of switching to latanoprost therapy in patients with deepening of the upper eyelid sulcus caused by travoprost and bimatoprost...
  24. ncbi Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension
    Richard Fiscella
    Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois 60612, USA
    Drugs Aging 23:39-47. 2006
    ..The objective of the present study was to compare the cost effectiveness of bimatoprost with that of latanoprost in the treatment of glaucoma and ocular hypertension...
  25. ncbi Use of oxytocin and cloprostenol to facilitate semen collection by electroejaculation or transrectal massage in bulls
    C W Palmer
    Department of Large Animal Clinical Sciences, University of Saskatchewan, Saskatoon, Sask, Canada S7N 5B4
    Anim Reprod Sci 80:213-23. 2004
    ..control); saline 10 min prior to 2 min of transrectal massage followed by electroejaculation; cloprostenol (CLO) 10 min prior to 2 min of transrectal massage followed by electroejaculation; oxytocin (OXY) 10 min prior ..
  26. ncbi Effects of dose and route of administration of cloprostenol on luteolysis, estrus and ovulation in beef heifers
    Marcos German Colazo
    Department of Large Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, 52 Campus Drive, Saskatoon, Sask, Canada S7N 5B4
    Anim Reprod Sci 72:47-62. 2002
    ..were conducted (with crossbred beef heifers) to determine the effects of dose and route of administration of cloprostenol on luteolysis, estrus and ovulation...
  27. pmc Cellular basis for bimatoprost effects on human conventional outflow
    W Daniel Stamer
    Department of Ophthalmology and Vision Science, The University of Arizona, Tucson, Arizona 85711, USA
    Invest Ophthalmol Vis Sci 51:5176-81. 2010
    ..The present study specifically examines bimatoprost effects on the cells that populate human outflow tissues...
  28. doi Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells
    Francoise Brignole-Baudouin
    Paris, France
    Curr Eye Res 36:979-88. 2011
    ..004% ophthalmic solution (travoprost BAK) and BAK-preserved latanoprost 0.005% ophthalmic solution (latanoprost BAK)...
  29. pmc Evaluation of monkey intraocular pressure by rebound tonometer
    Wenhan Yu
    Ophthalmic Laboratories and Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China
    Mol Vis 15:2196-201. 2009
    ..To evaluate the usefulness of the TonoVet rebound tonometer in measuring intraocular pressure (IOP) of monkeys...
  30. doi Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and non-pigmented ciliary epithelial cell lines
    David A Ammar
    Rocky Mountain Lions Eye Institute, Department of Ophthalmology, University of Colorado Denver, Aurora, CO 80045, USA
    Br J Ophthalmol 95:1466-9. 2011
    ..We investigated the potential cytotoxicity of various topical ophthalmic glaucoma formulations containing different preservatives in cultured human trabecular meshwork (TM) and non-pigmented ciliary epithelial (NPCE) cell lines...
  31. ncbi Quantitative analysis of conjunctival goblet cells after chronic application of topical drops
    Malik Y Kahook
    University of Colorado Health Sciences Center, Aurora, Colorado, USA
    Adv Ther 25:743-51. 2008
    ..02% benzalkonium chloride (BAK) eye drops (Xalatan; Pfizer, NY, USA), travoprost preserved with sofZia eye drops (Travatan Z; Alcon, Fort Worth, TX, USA), or preservative-free artificial tears (Refresh Plus; Allergan, Irvine, CA, USA)...
  32. pmc Prostamides (prostaglandin-ethanolamides) and their pharmacology
    D F Woodward
    Department of Biological Sciences, Allergan Inc, Irvine, CA 92612, USA
    Br J Pharmacol 153:410-9. 2008
    ..From the therapeutics standpoint, the prostamide F(2alpha) analogue bimatoprost is the most efficacious ocular hypotensive agent currently available for the treatment of glaucoma...
  33. pmc Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model
    Su Khoh-Reiter
    Drug Safety Research and Development, Pfizer Inc, San Diego, CA 92121, USA
    BMC Ophthalmol 9:5. 2009
    ....
  34. ncbi Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost
    Stefano A Gandolfi
    Glaucoma Service, Institute of Ophthalmology, University of Parma, Via Gramsci 14, 43100 Parma, Italy
    Ophthalmology 110:609-14. 2003
    ..To test the efficacy of bimatoprost 0.03% 2D for lowering intraocular pressure (IOP) in patients affected by primary open-angle glaucoma or ocular hypertension who did not respond to treatment with latanoprost 0.005% 2D...
  35. ncbi 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial
    Thomas R Walters
    Keystone Research, Austin, Texas, USA
    Surv Ophthalmol 49:S26-35. 2004
    ..To compare the efficacy and safety of once-daily (QD) bimatoprost, latanoprost, and timolol gel-forming solution in providing 24-hour intraocular pressure (IOP) control...
  36. ncbi Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs
    Dan L Eisenberg
    Shepherd Eye Center, Las Vegas, NV, USA
    Surv Ophthalmol 47:S105-15. 2002
    ..The side effect profiles for bimatoprost, latanoprost, and travoprost were similar, but with statistically higher occurrences of hyperemia and eyelash growth for bimatoprost or travoprost versus latanoprost or timolol...
  37. ncbi Bimatoprost and prostaglandin F(2 alpha) selectively stimulate intracellular calcium signaling in different cat iris sphincter cells
    Clayton S Spada
    Department of Biological Sciences, Pharmaceutical Research and Development, Allergan, Inc, Irvine, CA 92612 1599, USA
    Exp Eye Res 80:135-45. 2005
    ..These studies provide further evidence for the existence of a bimatoprost-sensitive receptor that is distinct from any of the known prostaglandin receptor types...
  38. ncbi In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells
    Jean Marc Guenoun
    Department of Ophthalmology, Quinze Vingts National Ophthalmology Hospital, Paris, France
    Invest Ophthalmol Vis Sci 46:2444-50. 2005
    ..e., conjunctival hyperemia)...
  39. ncbi The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice
    Takashi Ota
    Department of Ophthalmology, University of Tokyo School of Medicine, Japan
    Invest Ophthalmol Vis Sci 46:4159-63. 2005
    ..This study was designed to clarify the involvement of the prostanoid FP receptor in the intraocular pressure (IOP)-lowering effects of latanoprost, travoprost, bimatoprost, and unoprostone with the use of FP-receptor-deficient (FPKO) mice...
  40. ncbi A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma
    Monte S Dirks
    Black Hills Regional Eye Institute, Rapid City, SD 57701, USA
    Adv Ther 23:385-94. 2006
    ..Bimatoprost was found to be more effective than latanoprost in lowering IOP in the patient with normal-tension glaucoma. Both drugs were efficacious and well tolerated...
  41. doi The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence
    Thom J Zimmerman
    Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, Kentucky 40207, USA
    J Ocul Pharmacol Ther 25:145-52. 2009
    ..To document patient/physician perceptions of adverse effects and their relationship to medication changes among patients prescribed prostaglandin analogs...
  42. ncbi The pharmacology of bimatoprost (Lumigan)
    D F Woodward
    Allergan, Inc, Irvine, CA 92612, USA
    Surv Ophthalmol 45:S337-45. 2001
    ..The sclera is the preferred route of accession to the eye. The high scleral permeability coefficient Papp is a likely contributing factor to the rapid onset and long-acting ocular hypotensive profile of bimatoprost...
  43. ncbi Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy
    Richard A Lewis
    Grutzmacher and Lewis, Inc, Sacramento, CA, USA
    J Glaucoma 16:98-103. 2007
    ..To compare the safety and efficacy of travoprost 0.004% without benzalkonium chloride (BAC) to that of the marketed formulation of travoprost 0.004% in patients with open-angle glaucoma or ocular hypertension...
  44. ncbi Synthesis of prostaglandin F ethanolamide by prostaglandin F synthase and identification of Bimatoprost as a potent inhibitor of the enzyme: new enzyme assay method using LC/ESI/MS
    Noriko Koda
    Division of Life Science, Graduate School of Integrated Science and Art, University of East Asia, 2 1 Ichinomiyagakuen cho, Shimonoseki, Yamaguchi 751 8503, Japan
    Arch Biochem Biophys 424:128-36. 2004
    ..These results suggest that Bimatoprost also behaves as a potent PGF synthase inhibitor in addition to having prostamide-like activity...
  45. ncbi Comparative evaluation of bimatoprost monotherapy in primary chronic angle closure and primary open angle glaucoma eyes: a three-year study
    Viney Gupta
    Department of Ophthalmology, Glaucoma Research Facility and Clinical Services, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India
    J Ocul Pharmacol Ther 23:351-8. 2007
    ..The aim of this study was to compare the long-term efficacy of bimatoprost 0.03% monotherapy in primary open angle glaucoma (POAG) versus primary chronic angle closure glaucoma (PCACG) eyes...
  46. ncbi Comparison of prostaglandin F2alpha, bimatoprost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression
    Yanbin Liang
    Allergan, Inc, Irvine, California 92612, USA
    J Biol Chem 278:27267-77. 2003
    ..Thus, despite quite different signal transduction pathways, FP receptor stimulation up-regulates CTGF and Cyr61. The prostamide analog Bimatoprost and an EP2-selective agonist affects only Cyr61...
  47. doi Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study
    Constance O Okeke
    Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Ophthalmology 116:191-9. 2009
    ..To assess patient adherence and behaviors with topical once-daily therapy for glaucoma...
  48. ncbi Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension
    Jess T Whitson
    UT Southwestern Medical Center, Dallas, Texas 75390 8866, USA
    J Ocul Pharmacol Ther 26:287-92. 2010
    ..005% preserved with 0.02% benzalkonium chloride (BAK), bimatoprost 0.03% preserved with 0.005% BAK, and travoprost 0.004% preserved with the proprietary preservative system sofZia in patients previously treated with latanoprost...
  49. ncbi Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial
    Enyr S Arcieri
    Glaucoma Service, Department of Ophthalmology, University of Campinas, Campinas, Sao Paulo, Brazil
    Arch Ophthalmol 123:186-92. 2005
    ..To investigate the effects of prostaglandin analogues on the blood-aqueous barrier and to evaluate the occurrence of cystoid macular edema in aphakic or pseudophakic patients with glaucoma...
  50. ncbi [Ocular hemodynamics in normal tension glaucoma: effect of bimatoprost]
    O Zeitz
    Universitatsklinikum Hamburg Eppendorf, Klinik und Poliklinik für Augenheilkunde, Hamburg, Germany
    Klin Monbl Augenheilkd 221:550-4. 2004
    ..In the present study the effects of bimatoprost, which has recently been shown to increase the vascular tone of ciliary arteries in vitro, on the blood flow velocity are investigated...
  51. ncbi Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost
    Martin Kaback
    Glaucoma Consultants, Slingerlands, NY, USA
    Curr Med Res Opin 20:1341-5. 2004
    ..To evaluate the efficacy of travoprost 0.004% monotherapy in patients unsuccessfully treated with latanoprost monotherapy...
  52. ncbi Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system
    Richard W Yee
    Department of Ophthalmology Hermann Eye Center, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Adv Ther 23:511-9. 2006
    ..004% preserved without BAK showed significantly less toxicity on HCEs than did latanoprost 0.005%. This difference may have ramifications in terms of tolerability for patients who use these topical glaucoma drugs on a long-term basis...
  53. ncbi Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study
    Harry A Quigley
    Glaucoma Service and Dana Center for Preventive Ophthalmology, Wilmer Ophthalmological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ophthalmology 114:1599-606. 2007
    ..To perform a chart review to measure the validity of large claims databases in estimating patient cooperation with eyedrop therapy and to assess physician adherence with guidelines for a preferred practice pattern (PPP) using a new metric...
  54. ncbi Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%
    J Garcia-Feijoo
    Ophthalmology Department, Hospital Clinico San Carlos, Universidad Complutense, Madrid, Spain
    Curr Med Res Opin 22:1689-97. 2006
    ..004% ophthalmic solution (Travatan) compared to latanoprost 0.005% (Xalatan) dosed once daily in patients with primary open-angle glaucoma or ocular hypertension...
  55. ncbi Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients
    Anastasios G P Konstas
    Glaucoma Unit, Department of Ophthalmology, A University, Thessaloniki, Greece
    Ophthalmology 114:653-7. 2007
    ..To evaluate 24-hour intraocular pressure (IOP) efficacy of latanoprost versus travoprost, each given every evening, in exfoliative glaucoma patients...
  56. pmc Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension
    L B Cantor
    Department of Ophthalmology, Indiana University Medical Center, 702 Rotary Circle, Indianapolis, IN 46202, USA
    Br J Ophthalmol 90:1370-3. 2006
    ..To evaluate the efficacies of bimatoprost and travoprost for lowering of intraocular pressure (IOP) for the treatment of glaucoma and ocular hypertension...
  57. ncbi Efficiency of instillation methods for prostaglandin medications
    Richard Fiscella
    Department of Ophthalmology, University of Chicago, Chicago, IL 60612, USA
    J Ocul Pharmacol Ther 22:477-82. 2006
    ..The aim of this study was to determine the most efficient methods for instillation of prostaglandin analogs...
  58. ncbi Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride
    Jess T Whitson
    Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9057, USA
    Adv Ther 23:663-71. 2006
    ..004% preserved without BAK did not cause corneal epithelial toxicity; latanoprost 0.005% induced superficial cell loss, most likely caused by the presence of a relatively high concentration of BAK (0.02%)...
  59. ncbi A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma
    S Parmaksiz
    Department of Ophthalmology, School of Medicine, Kocaeli University, Kocaeli, Turkey
    Eur J Ophthalmol 16:73-80. 2006
    ..To compare the intraocular pressure (IOP) lowering effect and safety of latanoprost, travoprost given every evening, and the fixed combination dorzolamide + timolol (DTFC) given twice daily in pseudoexfoliation glaucoma (PXG)...
  60. ncbi Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension
    Nicola Orzalesi
    Eye Clinic, Department of Medicine, Surgery and Odontoiatry, University of Milan San Paolo Hospital, Milan, Italy
    Ophthalmology 113:239-46. 2006
    ..To compare 24-hour reduction in intraocular pressure (IOP) by latanoprost 0.005%, travoprost 0.004%, and bimatoprost 0.03% in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH)...
  61. ncbi Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study
    D Chiselita
    1st Eye Clinic, University of Medicine and Pharmacy, Iasi
    Oftalmologia 49:39-45. 2005
    ..To analyse comparatively the efficacy and tolerance of latanoprost, travoprost and the fixed combination timolol-dorzolamide in the treatment of primary open angle glaucoma and ocular hypertension...
  62. pmc Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study
    A G P Konstas
    Glaucoma Unit, A University Department of Ophthalmology, AHEPA Hospital, 1 Kyriakidi Str, Thessaloniki 546 36, Greece
    Br J Ophthalmol 91:757-60. 2007
    ..To evaluate the diurnal intraocular pressure (IOP) control and safety of bimatoprost versus latanoprost in exfoliative glaucoma (XFG)...
  63. ncbi 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma
    Anastasios G P Konstas
    Glaucoma Unit, Department of Ophthalmology, A University, AHEPA Hospital, Thessaloniki, Greece
    Ophthalmology 113:446-50. 2006
    ..To evaluate the quality of 24-hour intraocular pressure (IOP) control between morning- and evening-dosed travoprost in primary open-angle glaucoma patients...
  64. ncbi Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication
    Gabor Hollo
    Department of Ophthalmology, Semmelweis University, Budapest, Hungary
    Curr Med Res Opin 21:1943-8. 2005
    ..To investigate the influence of switching to travoprost on intraocular pressure (IOP) of chronic open-angle glaucoma (COAG) patients...
  65. ncbi Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma
    Stefan Holmstrom
    Allergan Europe, Pforzheimer Str 160, D 76275 Ettlingen, Germany
    Curr Med Res Opin 21:1875-83. 2005
    ..Study arms of timolol in trials including the above mentioned lipid class drugs were also included...
  66. ncbi In vitro comparison of cytoprotective and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells
    Jean Marc Guenoun
    Department of Ophthalmology, Quinze Vingts National Ophthalmology Hospital, Paris France
    Invest Ophthalmol Vis Sci 46:4594-9. 2005
    ....
  67. ncbi A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy
    Ph Denis
    Hopital Edouard Herriot, Service d Ophtalmologie, 5, place Arsonval, F 69003 Lyon, France
    Curr Med Res Opin 23:601-8. 2007
    ..To compare the efficacy of latanoprost, bimatoprost and travoprost for lowering IOP in patients with glaucoma...
  68. ncbi Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid Health Maintenance Organization
    Simon K Law
    Jules Stein Eye Institute, University of California, Los Angeles, California 90095, USA
    Ophthalmology 112:2123-30. 2005
    ..To assess the feasibility of an automatic switch of a large number of patients with glaucoma or suspicion of glaucoma from latanoprost to bimatoprost, and to compare the efficacy of the 2 prostaglandin analogs before and after the switch...
  69. ncbi A gap analysis approach to assess patient persistence with glaucoma medication
    Paul P Lee
    Duke Eye Center, Duke University, Durham, North Carolina, USA
    Am J Ophthalmol 144:520-4. 2007
    ..To develop an alternative method for analysis of patient persistence with prescribed medications using the prostaglandin class of intraocular pressure (IOP)-lowering drugs as a model...
  70. ncbi Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension
    Louis B Cantor
    Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Surv Ophthalmol 49:S12-8. 2004
    ..To evaluate the IOP-lowering efficacy of bimatoprost and travoprost for the treatment of glaucoma and ocular hypertension...
  71. doi A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma
    A C S How
    Singapore National Eye Centre, Singapore
    Br J Ophthalmol 93:782-6. 2009
    ..To compare the intraocular pressure (IOP) lowering efficacy and side effects of latanoprost 0.005% and bimatoprost 0.03% in subjects with chronic primary angle closure glaucoma (PACG)...
  72. ncbi Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension
    Robert M Feldman
    University of Texas Health Sciences Center, Houston, USA
    J Ocul Pharmacol Ther 19:23-35. 2003
    ..Until more definitive data are available, when selecting a prostaglandin analogue for ocular hypotensive therapy, it seems prudent to choose an agent with a low incidence of hyperemia...
  73. ncbi Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost
    William C Stewart
    Pharmaceutical Research Corporation, Charleston, South Carolina 29412 2464, USA
    Am J Ophthalmol 135:314-20. 2003
    ..To evaluate conjunctival hyperemia after short-term use of latanoprost 0.005%, bimatoprost 0.03% and travoprost 0.004% in normal adults...
  74. ncbi Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost
    H DuBiner
    Clayton Eye Center, Morrow, GA, USA
    Surv Ophthalmol 45:S353-60. 2001
    ..CONCLUSIONS: At the end of this 30-day trial, once-daily bimatoprost 0.03% provided better diurnal IOP control than latanoprost and was safe and well tolerated in patients with ocular hypertension and glaucoma...
  75. ncbi One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension
    Eve J Higginbotham
    Department of Ophthalmology, University of Maryland at Baltimore, 419 W Redwood St, Suite 580, Baltimore, MD 21201 1595, USA
    Arch Ophthalmol 120:1286-93. 2002
    ..To compare bimatoprost with timolol maleate in patients with glaucoma or ocular hypertension...
  76. ncbi Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist
    Mark R Hellberg
    Department of Medicinal Chemistry, Alcon Research Ltd, 6201 South Freeway, Fort Worth, TX 76134, USA
    Surv Ophthalmol 47:S13-33. 2002
    ..The acute and, apparently, conjunctival hyperemia associated with topical ocular AL-6598 can be attenuated while maintaining intraocular pressure-lowering efficacy by formulating with brimonidine...
  77. ncbi Eyelash enhancement properties of topical dechloro ethylcloprostenolamide
    Isaac Choy
    Laser and Cosmetics, San Mateo, CA 94401, USA
    J Cosmet Laser Ther 10:110-3. 2008
    ..To assess subjective reports by users of MD Lash Factor(TM) that it improved the appearance of their eyelashes, especially in length...
  78. doi Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4
    R D Williams
    Taustine Eye Center, Louisville, KY 40207, USA
    Br J Ophthalmol 92:1387-92. 2008
    ..5% over 2 years. To further evaluate long-term safety and efficacy, once-daily bimatoprost 0.03% was compared with timolol 0.5% twice daily through year 4...
  79. ncbi Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension
    P A Netland
    Department of Ophthalmology, University of Tennessee Health Science Center, 956 Court Ave, Memphis, TN 38163, USA
    Am J Ophthalmol 132:472-84. 2001
    ..0015% and 0.004%) compared with latanoprost 0.005% and timolol 0.5% in patients with open-angle glaucoma or ocular hypertension...
  80. ncbi Comparison of corneal wound healing rates after instillation of commercially available latanoprost and travoprost in rat debrided corneal epithelium
    Noriaki Nagai
    School of Pharmacy, Kinki University, Osaka, Japan
    J Oleo Sci 59:135-41. 2010
    ..Travoprost eye drops with sofzia may provide effective therapy for glaucoma patients using long-term ophthalmic agents...
  81. ncbi Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension
    S Gandolfi
    University of Parma, Via Gramsci 14, Parma, 43100, Italy
    Adv Ther 18:110-21. 2001
    ..Bimatoprost provided lower mean pressures than latanoprost at every time point throughout the study and was statistically superior in achieving low target pressures. More patients reached low target pressures with bimatoprost...
  82. ncbi Luteal and clinical response following administration of dinoprost tromethamine or cloprostenol at standard intramuscular sites or at the lumbosacral acupuncture point in mares
    G J Nie
    Department of Large Animal Surgery and Medicine, College of Veterinary Medicine, Auburn University, AL 36849-5522, USA
    Am J Vet Res 62:1285-9. 2001
    ..PROCEDURE: Conventional and microdoses of the prostaglandin dinoprost tromethamine (PGF2alpha), the analogue cloprostenol, or sterile water (control) were administered to mares in 7 treatment groups...
  83. ncbi Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management
    R A Laibovitz
    Eye Research Associates, Austin TX, USA
    Arch Ophthalmol 119:994-1000. 2001
    ..AGN 192024 was safe and well tolerated, and it provided superior ocular hypotensive efficacy and diurnal IOP control compared with timolol in patients with ocular hypertension and glaucoma...
  84. ncbi Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure
    M Sherwood
    Department of Ophthalmology, University of Florida College of Medicine, Gainesville, FL 32610 0284, USA
    Surv Ophthalmol 45:S361-8. 2001
    ..Together these results indicate that bimatoprost QD is statistically and clinically superior to timolol in lowering IOP, and is safe and well-tolerated in patients with glaucoma or ocular hypertension...
  85. ncbi Mechanism of action of bimatoprost (Lumigan)
    R F Brubaker
    Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA
    Surv Ophthalmol 45:S347-51. 2001
    ..The former effect is common to all ocular hypotensive drugs, but the latter effect is an exclusive property of drugs that reduce outflow resistance, such as bimatoprost...
  86. ncbi A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study
    Richard K Parrish
    Bascom Palmer Eye Institute, Miami, Florida 33136, USA
    Am J Ophthalmol 135:688-703. 2003
    ..To Internet Advance publication at ajo.com Feb 13, 2003. compare the intraocular pressure (IOP)-lowering effect and safety of latanoprost, bimatoprost, and travoprost in patients with open-angle glaucoma (OAG) or ocular hypertension (OH)...
  87. doi Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears
    Malik Y Kahook
    Department of Ophthalmology, The Rocky Mountain Lions Eye Institute, University of Colorado Health Sciences Center, Aurora, CO, USA
    Cornea 27:339-43. 2008
    ..To evaluate corneal and conjunctival changes after chronic, once-daily dosing of travoprost preserved with sofZia, latanoprost preserved with 0.02% benzalkonium chloride (BAK), or preservative-free artificial tears...
  88. ncbi Effect of administering oxytocin or cloprostenol in the periovulatory period on pregnancy outcome and luteal function in mares
    Gary J Nie
    Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL 36849 5522, USA
    Theriogenology 60:1111-8. 2003
    Mares (n = 37) were treated from 4h after breeding through 2 days post-ovulation with oxytocin or cloprostenol. Oxytocin (20 units i.m.) was administered every 6 h and cloprostenol (250 mcg i.m.) daily...
  89. ncbi Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension
    Robert J Noecker
    Department of Ophthalmology, University of Arizona, Tucson 85711, USA
    Adv Ther 20:121-8. 2003
    ..After 3 months, the mean IOP reduction from baseline was 8.4 mm Hg (34%) in the bimatoprost group and 7.9 mm Hg (30%) in the travoprost group. These results are being evaluated further in a larger clinical trial...
  90. ncbi Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study
    Gregory Reardon
    Informagenics, LLC, Worthington, Ohio 43085, USA
    Clin Ther 25:1172-85. 2003
    ....
  91. ncbi In vivo corneal epithelial permeability following treatment with prostaglandin analogs [correction of analoges] with or without benzalkonium chloride
    Bernard McCarey
    Department of Ophthalmology, Emory University Eye Center, Atlanta, GA 30322, USA
    J Ocul Pharmacol Ther 23:445-51. 2007
    ..Agents such as travoprost Z with an alternative preservative decreased the epithelial toxicity associated with the long-term use of IOP-lowering agents preserved with BAK...
  92. ncbi A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%
    Eugenio Maul
    Pontificia Universidad Catolica, Santiago, Chile
    Clin Ther 29:1915-23. 2007
    ..004% versus latanoprost 0.005% for 6 weeks followed by 6 weeks of once-daily travoprost 0.004% in decreasing intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OH)...
  93. ncbi Efficacy and safety of a systematic switch from latanoprost to travoprost in patients with glaucoma
    Rajesh S Kumar
    Singapore National Eye Centre, Singapore
    J Glaucoma 16:606-9. 2007
    ..To assess the efficacy and safety of systematically switching a large number of hospital-based glaucoma patients from latanoprost to travoprost therapy...
  94. ncbi Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines
    William C Stewart
    PRN Pharmaceutical Research Network, LLC, Dallas, Texas, USA
    Ophthalmology 115:1117-1122.e1. 2008
    ....
  95. doi Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials
    Rohit Varma
    Keck School of Medicine, University of Southern California, 1450 San Pablo Street, Los Angeles, CA 90033, USA
    Am J Ophthalmol 145:336-42. 2008
    ..To evaluate whether inter-visit intraocular pressure (IOP) range, which reflects extreme and potentially damaging IOP fluctuations, provides additional information on IOP control compared to mean IOP...
  96. ncbi Treatment carryover impacts on effectiveness of intraocular pressure lowering agents, estimated by a discrete event simulation model
    P Denis
    Hopital Edouard Herriot, Lyon, France
    Eur J Ophthalmol 18:44-51. 2008
    ....
  97. ncbi The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy
    Elizabeth D Sharpe
    Glaucoma Consultants and Center For Eye Research, Mount Pleasant, South Carolina, USA
    Curr Eye Res 32:1037-43. 2007
    ..To evaluate the incidence and characteristics of periocular pigmentation with latanoprost versus bimatoprost...
  98. pmc Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study
    K Sheng Lim
    Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA
    Ophthalmology 115:790-795.e4. 2008
    ..To study the effects of 3 prostaglandin analogs, bimatoprost, latanoprost, and travoprost, on aqueous dynamics in the same subjects and to compare techniques of assessing outflow facility...
  99. ncbi A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective
    A Hommer
    Krankenanstalt Sanatorium, Vienna, Austria
    Curr Med Res Opin 24:1057-63. 2008
    ....
  100. ncbi Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial
    J D Brandt
    Department of Ophthalmology, University of California at Davis, Sacramento, California 95817-2307, USA
    Ophthalmology 108:1023-31; discussion 1032. 2001
    ..Once-daily dosing of bimatoprost, 0.03%, demonstrated greater IOP-lowering effect and better ocular tolerability than twice-daily dosing...
  101. ncbi Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure
    Luca Rossetti
    Clinica Oculistica, Dipartimento di Medicina, Chirurgia e Odontoiatria, Universita di Milano, Ospedale San Paolo, Milan, Italy
    Ophthalmology 114:2244-51. 2007
    ..To compare the effect of bimatoprost and the fixed combination of latanoprost and timolol (LTFC) on 24-hour mean intraocular pressure (IOP) after patients are switched from a nonfixed combination of latanoprost and timolol...

Research Grants86

  1. PREVALENCE AND IMPACT OF GLAUCOMA AMONG THE VERY ELDERLY
    David Friedman; Fiscal Year: 2003
    ..Finally, the interactions between comorbidities (including cognitive deficits) and visual field loss will be explored. ..
  2. PREVALENCE AND IMPACT OF GLAUCOMA AMONG THE VERY ELDERLY
    David Friedman; Fiscal Year: 2002
    ..Finally, the interactions between comorbidities (including cognitive deficits) and visual field loss will be explored. ..
  3. PREVALENCE AND IMPACT OF GLAUCOMA AMONG THE VERY ELDERLY
    David Friedman; Fiscal Year: 2001
    ..Finally, the interactions between comorbidities (including cognitive deficits) and visual field loss will be explored. ..
  4. CADHERIN DYNAMICS AND GLAUCOMA
    W Daniel Stamer; Fiscal Year: 2010
    ..Results obtained from these investigations will provide a basic understanding of the role of cadherin proteins in aqueous outflow resistance and uncover novel therapeutic targets for glaucoma therapy. ..
  5. OHTS--KRESGE EYE INSTITUTE
    Bret Hughes; Fiscal Year: 2004
    ....
  6. OCULAR HYPERTENSION TREATMENT STUDY (OHTS)
    James Brandt; Fiscal Year: 2004
    ....
  7. Molecular Basis of Myocilin Function in the Human Eye
    W Stamer; Fiscal Year: 2005
    ..This knowledge will contribute to our understanding of glaucoma at the molecular level and provide new therapeutic targets for the treatment of those who are afflicted with glaucoma. ..
  8. CIGTS-2 Optic Disc Reading Center
    Richard Parrish; Fiscal Year: 2005
    ..To provide the Coordinating Center with optic disc progression rates ..
  9. Improving the Quality of Diabetes Eye Care
    Paul Lee; Fiscal Year: 2005
    ..The insights from the study results should be applicable to other areas of diabetes care and health care in general. ..
  10. NOVEL GLAUCOMA DIAGNOSTICS FOR STRUCTURE AND FUNCTION
    Joel Schuman; Fiscal Year: 2004
    ..National Plan Strategic Research Question, "What is the relationship between visual function loss and structural changes to the optic nerve and retinal nerve fiber layer in glaucoma?" [National Advisory Eye Council 1999] ..
  11. COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY
    Ronald Gross; Fiscal Year: 2003
    ....
  12. COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY
    Rohit Varma; Fiscal Year: 2003
    ....
  13. CADHERIN REGULATION OF AQUEOUS HUMOR OUTFLOW
    W Stamer; Fiscal Year: 2004
    ..abstract_text> ..
  14. CIGTS-2 Optic Disc Reading Center
    Richard Parrish; Fiscal Year: 2003
    ..To provide the Coordinating Center with optic disc progression rates ..
  15. LOS ANGELES LATINO EYE STUDY
    Rohit Varma; Fiscal Year: 2003
    ..The data will help predict the eye care needs of and will aid in developing prevention and intervention programs for this largest and fastest growing minority in the United States. ..
  16. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 2003
    ..The studies proposed here have already suggested several new avenues of non-intraocular pressure lowering therapy for glaucoma. ..
  17. NOVEL GLAUCOMA DIAGNOSTICS FOR STRUCTURE AND FUNCTION
    Joel Schuman; Fiscal Year: 2003
    ..National Plan Strategic Research Question, "What is the relationship between visual function loss and structural changes to the optic nerve and retinal nerve fiber layer in glaucoma?" [National Advisory Eye Council 1999] ..
  18. Multiethnic Pediatric Eye Disease Study (MEPEDS)
    Rohit Varma; Fiscal Year: 2004
    ..MEPEDS will also be studying selected demographic, biological and behavioral risk factors associated with these diseases and the consequences of these diseases from a health related quality of life perspective. ..
  19. NOVEL GLAUCOMA DIAGNOSTICS FOR STRUCTURE AND FUNCTION
    Joel Schuman; Fiscal Year: 2005
    ..This project addresses the Strategic Research Priorities stated in the National Plan for Vision Research, to ".. .develop improved diagnostic measures to detect optic nerve disease onset, progression, and treatment effectiveness." ..
  20. CADHERIN DYNAMICS AND GLAUCOMA
    W Stamer; Fiscal Year: 2006
    ..Results obtained from these investigations will provide a basic understanding of the role of cadherin proteins in aqueous outflow resistance and uncover novel therapeutic targets for glaucoma therapy. [unreadable] [unreadable]..
  21. NOVEL GLAUCOMA DIAGNOSTICS FOR STRUCTURE AND FUNCTION
    Joel Schuman; Fiscal Year: 2009
    ..This project addresses the Strategic Research Priorities stated in the National Plan for Vision Research, to ".. .develop improved diagnostic measures to detect optic nerve disease onset, progression, and treatment effectiveness." ..
  22. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 2008
    ..Candidate molecules for genetic susceptibility to glaucoma are likely to be identified. ..
  23. Wilmer Inst. Mentored Clinical Research Scholar Program
    Harry Quigley; Fiscal Year: 2008
    ..The Wilmer CRS will administer didactic courses and personal mentored instruction in a wide variety of research areas to 2 candidates per year. ..
  24. Multiethnic Pediatric Eye Disease Study (MEPEDS)
    Rohit Varma; Fiscal Year: 2008
    ..MEPEDS will also be studying selected demographic, biological and behavioral risk factors associated with these diseases and the consequences of these diseases from a health related quality of life perspective. ..
  25. CADHERIN DYNAMICS AND GLAUCOMA
    W Stamer; Fiscal Year: 2009
    ..Results obtained from these investigations will provide a basic understanding of the role of cadherin proteins in aqueous outflow resistance and uncover novel therapeutic targets for glaucoma therapy. ..
  26. Expanding Quality Care for Glaucoma through a Provider-Patient Partnership
    Paul Lee; Fiscal Year: 2008
    ..Further, such techniques would provide insights to assist non-physician providers to provide high quality care throughout health care. ..
  27. NOVEL GLAUCOMA DIAGNOSTICS FOR STRUCTURE AND FUNCTION
    Joel Schuman; Fiscal Year: 2008
    ..This project addresses the Strategic Research Priorities stated in the National Plan for Vision Research, to ".. .develop improved diagnostic measures to detect optic nerve disease onset, progression, and treatment effectiveness." ..
  28. CADHERIN DYNAMICS AND GLAUCOMA
    W Stamer; Fiscal Year: 2008
    ..Results obtained from these investigations will provide a basic understanding of the role of cadherin proteins in aqueous outflow resistance and uncover novel therapeutic targets for glaucoma therapy. ..
  29. Expanding Quality Care for Glaucoma through a Provider-Patient Partnership
    Paul Lee; Fiscal Year: 2007
    ..Further, such techniques would provide insights to assist non-physician providers to provide high quality care throughout health care. ..
  30. NOVEL GLAUCOMA DIAGNOSTICS FOR STRUCTURE AND FUNCTION
    Joel Schuman; Fiscal Year: 2007
    ..This project addresses the Strategic Research Priorities stated in the National Plan for Vision Research, to ".. .develop improved diagnostic measures to detect optic nerve disease onset, progression, and treatment effectiveness." ..
  31. Wilmer Inst. Mentored Clinical Research Scholar Program
    Harry Quigley; Fiscal Year: 2007
    ..The Wilmer CRS will administer didactic courses and personal mentored instruction in a wide variety of research areas to two candidates per year. [unreadable] [unreadable] [unreadable]..
  32. Multiethnic Pediatric Eye Disease Study (MEPEDS)
    Rohit Varma; Fiscal Year: 2007
    ..MEPEDS will also be studying selected demographic, biological and behavioral risk factors associated with these diseases and the consequences of these diseases from a health related quality of life perspective. ..
  33. CADHERIN DYNAMICS AND GLAUCOMA
    W Stamer; Fiscal Year: 2007
    ..Results obtained from these investigations will provide a basic understanding of the role of cadherin proteins in aqueous outflow resistance and uncover novel therapeutic targets for glaucoma therapy. [unreadable] [unreadable]..
  34. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    HARRY ALAN QUIGLEY; Fiscal Year: 2010
    ..To complete the project in 2 years, we eliminated from the 5 year proposal Hypotheses 7, 8, 9, and 11. ..
  35. Improving the Quality of Diabetes Eye Care
    Paul Lee; Fiscal Year: 2006
    ..The insights from the study results should be applicable to other areas of diabetes care and health care in general. ..
  36. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 2006
    ..The studies proposed here have already suggested several new avenues of non-intraocular pressure lowering therapy for glaucoma. ..
  37. Multiethnic Pediatric Eye Disease Study (MEPEDS)
    Rohit Varma; Fiscal Year: 2002
    ..MEPEDS will also be studying selected demographic, biological and behavioral risk factors associated with these diseases and the consequences of these diseases from a health related quality of life perspective. ..
  38. COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY
    Rohit Varma; Fiscal Year: 2002
    ....
  39. NOVEL GLAUCOMA DIAGNOSTICS FOR STRUCTURE AND FUNCTION
    Joel Schuman; Fiscal Year: 2000
    ..National Plan Strategic Research Question, "What is the relationship between visual function loss and structural changes to the optic nerve and retinal nerve fiber layer in glaucoma?" [National Advisory Eye Council 1999] ..
  40. ENDOGENOUS REGULATION OF INTRAOCULAR PRESSURE
    John Liu; Fiscal Year: 2000
    ..This information should be useful for the development of antiglaucoma medicines. The human studies may lead to further studies in glaucoma patients and possibly a refinement of glaucoma therapy. ..
  41. THE PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 1980
  42. ENDOGENOUS REGULATION OF AQUEOUS HUMOR DYNAMICS
    John Liu; Fiscal Year: 1993
    ..This new knowledge should benefit relevant research in other species and help to refine the rationale for developing more effective antiglaucoma treatment...
  43. ENDOGENOUS REGULATION OF INTRAOCULAR PRESSURE
    John Liu; Fiscal Year: 1999
    ..This information should be useful for the development of antiglaucoma medicines. The human studies may lead to further studies in glaucoma patients and possibly a refinement of glaucoma therapy. ..
  44. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 1991
    ....
  45. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 1999
    ..In these rats, induced neuronal expression will be studied in a chronic glaucoma model to assess beneficial effects. ..
  46. ENDOGENOUS REGULATION OF INTRAOCULAR PRESSURE
    John Liu; Fiscal Year: 2001
    ..This information should be useful for the development of antiglaucoma medicines. The human studies may lead to further studies in glaucoma patients and possibly a refinement of glaucoma therapy. ..
  47. NOVEL GLAUCOMA DIAGNOSTICS FOR STRUCTURE AND FUNCTION
    Joel Schuman; Fiscal Year: 2002
    ..National Plan Strategic Research Question, "What is the relationship between visual function loss and structural changes to the optic nerve and retinal nerve fiber layer in glaucoma?" [National Advisory Eye Council 1999] ..
  48. Molecular Basis of Myocilin Function in the Human Eye
    W Stamer; Fiscal Year: 2002
    ..This knowledge will contribute to our understanding of glaucoma at the molecular level and provide new therapeutic targets for the treatment of those who are afflicted with glaucoma. ..
  49. COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY
    Mark Sherwood; Fiscal Year: 2002
    ....
  50. ENDOGENOUS REGULATION OF INTRAOCULAR PRESSURE
    John Liu; Fiscal Year: 2002
    ..This information should be useful for the development of antiglaucoma medicines. The human studies may lead to further studies in glaucoma patients and possibly a refinement of glaucoma therapy. ..
  51. NOVEL GLAUCOMA DIAGNOSTICS FOR STRUCTURE AND FUNCTION
    Joel Schuman; Fiscal Year: 2001
    ..National Plan Strategic Research Question, "What is the relationship between visual function loss and structural changes to the optic nerve and retinal nerve fiber layer in glaucoma?" [National Advisory Eye Council 1999] ..
  52. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 2001
    ..In these rats, induced neuronal expression will be studied in a chronic glaucoma model to assess beneficial effects. ..
  53. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 1990
    ....
  54. NOVEL GLAUCOMA DIAGNOSTICS FOR STRUCTURE AND FUNCTION
    Joel Schuman; Fiscal Year: 2006
    ..This project addresses the Strategic Research Priorities stated in the National Plan for Vision Research, to ".. .develop improved diagnostic measures to detect optic nerve disease onset, progression, and treatment effectiveness." ..
  55. Molecular Basis of Myocilin Function in the Human Eye
    W Stamer; Fiscal Year: 2003
    ..This knowledge will contribute to our understanding of glaucoma at the molecular level and provide new therapeutic targets for the treatment of those who are afflicted with glaucoma. ..
  56. CIGTS-2 Optic Disc Reading Center
    Richard Parrish; Fiscal Year: 2004
    ..To provide the Coordinating Center with optic disc progression rates ..
  57. OCULAR HYPERTENSION TREATMENT STUDY (OHTS)
    Ronald Gross; Fiscal Year: 2004
    ....
  58. Molecular Basis of Myocilin Function in the Human Eye
    W Stamer; Fiscal Year: 2004
    ..This knowledge will contribute to our understanding of glaucoma at the molecular level and provide new therapeutic targets for the treatment of those who are afflicted with glaucoma. ..
  59. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 2000
    ..In these rats, induced neuronal expression will be studied in a chronic glaucoma model to assess beneficial effects. ..
  60. Expanding Quality Care for Glaucoma through a Provider-Patient Partnership
    Paul Lee; Fiscal Year: 2009
    ..Further, such techniques would provide insights to assist non-physician providers to provide high quality care throughout health care. ..
  61. OCULAR HYPERTENSION TREATMENT STUDY (OHTS)
    James Brandt; Fiscal Year: 2008
    ....
  62. COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY
    Mark Sherwood; Fiscal Year: 2003
    ....
  63. OHTS--KRESGE EYE INSTITUTE
    Bret Hughes; Fiscal Year: 2008
    ....
  64. LOS ANGELES LATINO EYE STUDY
    Rohit Varma; Fiscal Year: 2007
    ..The data will help predict the eye care needs of and will aid in developing prevention and intervention programs for this largest and fastest growing minority in the United States. ..
  65. Improving the Quality of Diabetes Eye Care
    Paul Lee; Fiscal Year: 2003
    ..The insights from the study results should be applicable to other areas of diabetes care and health care in general. ..
  66. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 1992
    ....
  67. OHTS--KRESGE EYE INSTITUTE
    Bret Hughes; Fiscal Year: 2007
    ....
  68. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 1993
    ....
  69. Improving the Quality of Diabetes Eye Care
    Paul Lee; Fiscal Year: 2004
    ..The insights from the study results should be applicable to other areas of diabetes care and health care in general. ..
  70. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 2004
    ..The studies proposed here have already suggested several new avenues of non-intraocular pressure lowering therapy for glaucoma. ..
  71. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 2002
    ..In these rats, induced neuronal expression will be studied in a chronic glaucoma model to assess beneficial effects. ..
  72. COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY
    Ronald Gross; Fiscal Year: 2002
    ....